In the ﬁeld of transplantation, CMV serology is performed on blood samples from the prospective organ donor and recipient to determine the risk of primary infection or reactivation of disease. The knowledge of these risks inﬂuences the type of preventive efforts for each patient population. Speciﬁcally, a CMV D+/R- mismatch SOT recipient has the highest risk of primary CMV disease, and therefore may beneﬁt from antiviral prophylaxis or aggressive CMV surveillance and pre- emptive therapy. Some centers have also used serology to determine ongoing risk of primary CMV disease after transplantation since seroconversion would suggest pro- tection from subsequent CMV disease
If you want to change selection, open document below and click on "Move attachment"
- (no access) - CMV ASM.pdf, p13
|status||not read|| ||reprioritisations|
|last reprioritisation on|| ||suggested re-reading day|
|started reading on|| ||finished reading on|